Revenue

Facing a cancer diagnosis is overwhelming. Manulife's new Cancer Coach program offers a lifeline with personalized support for daily life and work.

With €10M in new funding, Berlin-based Cellbricks is moving its biofabricated human tissues from lab to preclinical trials, promising a new era for patients.

Two major computer museums join a rental network, giving Hollywood unprecedented access to working vintage hardware for historically accurate productions.

Alongside Google and Nvidia, QuickFi's AI lending platform is revolutionizing the $1.3T equipment finance market. Here's how it's creating a new industry model.

Maze Therapeutics posts positive Phase 2 data for its genetic kidney disease drug, but a sharp stock drop reveals investor concerns in a competitive race.

Health Canada greenlights MeMed's rapid diagnostic tool, a major step in the nation's fight against deadly sepsis and growing antimicrobial resistance.

Following a 40-year career shaping biotech finance, Jessica Chutter's move to PTC's board signals major strategic ambitions for the rare disease firm.

A new partnership uses advanced AI to find unused grid capacity, slashing data center connection times from years to months and accelerating economic growth.

Chandigarh University makes major leaps in the 2026 QS Rankings, entering the top 300 in key engineering fields and reflecting India's growing global stature.

With a massive new launch, Suave is directly challenging luxury brands by offering high-performance 'dupes' at a fraction of the cost. Is this the new normal?

A battle for control erupts at Apimeds Pharmaceuticals as majority shareholders oust the board over a disputed 1000 bitcoin asset from a recent merger.

Private equity firm Etna Capital has acquired AI specialist CodeRoad, a strategic move betting on agentic AI and Latin America's growing tech talent pool.

Let's Talk Supply Chain's new Gemini integration transforms podcasts into dynamic, interactive learning tools for industry professionals.

With $138M in total funding, Endogenex is advancing a novel device that aims to redefine type 2 diabetes treatment by healing the gut, not just managing symptoms.

With a new $200M funding round, legal AI leader Harvey is now valued at $11 billion, signaling a fundamental shift in how law is practiced worldwide.

Biolojic Design's adaptive AI drug for asthma and eczema hits a key milestone with Teva, heralding a new era for personalized autoimmune treatment.

EV drivers get free parking and cheaper rates at Hilton Heathrow T5 as Roam's new initiative aims to redefine convenience at major transport hubs.

KNOT Offshore Partners' acquisition deal has been terminated, raising strategic questions. But a booming shuttle tanker market offers a powerful tailwind.

The firm leveraged its integrated insurance and investment model to achieve record revenue and a top-10 ranking while defying a looming advisor shortage.

With a new $20M in funding, Charlotte-based Lucid Bots is expanding its fleet of AI-powered drones and robots, transforming blue-collar work from the ground up.